MARKET

NXTC

NXTC

Nextcure
NASDAQ
0.5782
-0.0623
-9.73%
After Hours: 0.5799 +0.0017 +0.29% 19:45 03/18 EDT
OPEN
0.6600
PREV CLOSE
0.6405
HIGH
0.6700
LOW
0.5756
VOLUME
157.70K
TURNOVER
--
52 WEEK HIGH
2.570
52 WEEK LOW
0.5756
MARKET CAP
16.19M
P/E (TTM)
-0.2905
1D
5D
1M
3M
1Y
5Y
1D
NextCure Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Reiterates Buy on NextCure, Maintains $3 Price Target
Benzinga · 1d ago
Weekly Report: what happened at NXTC last week (0310-0314)?
Weekly Report · 1d ago
Weekly Report: what happened at NXTC last week (0303-0307)?
Weekly Report · 03/10 09:18
Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles
TipRanks · 03/08 06:02
NextCure Reports 2024 Financials and Strategic Progress
TipRanks · 03/08 04:03
HC Wainwright & Co. Reiterates Buy on NextCure, Lowers Price Target to $3
Benzinga · 03/07 12:26
Piper Sandler Sticks to Its Buy Rating for NextCure (NXTC)
TipRanks · 03/07 12:26
More
About NXTC
NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (ADCs), antibodies, and proteins. The Company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidates include NC410 and LNCB74. Its Clinical Oncology Programs are NC525 and NC318. Its Pre-Clinical Non-Oncology Programs are NC605 and NC181. NC410 is a LAIR-2 fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers. NCB74 is an ADC that is directed to B7-H4, a clinically validated cancer target.

Webull offers NextCure Inc stock information, including NASDAQ: NXTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NXTC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NXTC stock methods without spending real money on the virtual paper trading platform.